DiaSorin S.p.A. (OTCMKTS:DSRLF) Given Consensus Rating of “Hold” by Brokerages

DiaSorin S.p.A. (OTCMKTS:DSRLF) has received an average rating of “Hold” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company.

Several research firms have recently commented on DSRLF. UBS Group downgraded shares of DiaSorin from a “buy” rating to a “neutral” rating in a report on Thursday, April 9th. Zacks Research raised shares of DiaSorin to a “hold” rating in a report on Tuesday, May 12th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of DiaSorin in a report on Tuesday, February 10th.

DiaSorin Price Performance

DSRLF stock opened at $84.10 on Monday. The firm’s fifty day simple moving average is $69.53 and its 200-day simple moving average is $74.67. DiaSorin has a 12 month low of $66.50 and a 12 month high of $112.30.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.